此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

测试将抗癌病毒疗法 Telomelysin™ 添加到晚期食管癌且不适合手术的患者的放化疗中

2026年9月9日 更新者:NRG Oncology

OBP-301 (Telomelysin™) 扩展队列的 I 期试验和针对不适合手术的局部晚期食管癌和胃食管癌患者的最终放化疗

This phase I trial studies the side effects of OBP-301 when given together with carboplatin, paclitaxel, and radiation therapy in treating patients with esophageal or gastroesophageal cancer that invades local or regional structures. OBP-301 is a virus that has been designed to infect and destroy tumor cells (although there is a small risk that it can also infect normal cells). Chemotherapy drugs, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving OBP-301 with chemotherapy and radiation therapy may work better than standard chemotherapy and radiation therapy in treating patients with esophageal or gastroesophageal cancer.

研究概览

地位

主动,不招人

详细说明

PRIMARY OBJECTIVE:

I. To determine if the addition of OBP-301 to chemoradiation with carboplatin/paclitaxel is safe.

SECONDARY OBJECTIVES:

I. To assess toxicities associated with the addition of OBP-301 to chemoradiation.

II. To assess the number of clinical complete responses (cCR).

III. To assess the number of patients alive/without progression (progression-free survival [PFS]) and the number of patients alive (overall survival [OS]) at 1 and 2 years.

EXPLORATORY OBJECTIVE:

I. To report correlate outcomes - cCR, PFS and OS - with immune and virus-based correlative assays.

OUTLINE:

This study will evaluate an initial dose of OBP-301 and a de-escalated dose, if needed.

Patients receive OBP-301 by intratumoral injection via endoscopy on days -3, 12, and 26. Patients also receive carboplatin intravenously (IV) over 30 minutes and paclitaxel IV over 60 minutes on days 1, 8, 15, 22, and 29, and undergo radiation therapy on Monday through Friday beginning day 1 for 28 fractions over 5.5 weeks. All treatment continues in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 1 and 6-8 weeks, then every 3 months for 2 years.

研究类型

介入性

注册 (实际的)

16

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • California
      • Duarte、California、美国、91010
        • City of Hope Comprehensive Cancer Center
      • South Pasadena、California、美国、91030
        • City of Hope South Pasadena
      • Upland、California、美国、91786
        • City of Hope Upland
    • Florida
      • Tampa、Florida、美国、33612
        • Moffitt Cancer Center
    • Kansas
      • Fairway、Kansas、美国、66205
        • University of Kansas Clinical Research Center
      • Kansas City、Kansas、美国、66160
        • University of Kansas Cancer Center
      • Westwood、Kansas、美国、66205
        • University of Kansas Hospital-Westwood Cancer Center
    • Massachusetts
      • Boston、Massachusetts、美国、02114
        • Massachusetts General Hospital Cancer Center
    • New Jersey
      • Basking Ridge、New Jersey、美国、07920
        • Memorial Sloan Kettering Basking Ridge
      • Middletown、New Jersey、美国、07748
        • Memorial Sloan Kettering Monmouth
      • Montvale、New Jersey、美国、07645
        • Memorial Sloan Kettering Bergen
    • New York
      • Commack、New York、美国、11725
        • Memorial Sloan Kettering Commack
      • Harrison、New York、美国、10604
        • Memorial Sloan Kettering Westchester
      • New York、New York、美国、10065
        • Memorial Sloan Kettering Cancer Center
      • Uniondale、New York、美国、11553
        • Memorial Sloan Kettering Nassau
    • Ohio
      • Columbus、Ohio、美国、43210
        • Ohio State University Comprehensive Cancer Center
    • Texas
      • Houston、Texas、美国、77030
        • UT MD Anderson Cancer Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Pathologically (histologically or cytologically) proven diagnosis of adenocarcinoma or squamous cell carcinoma (SCC) of the esophagus or gastroesophageal junction (GEJ) within 90 days prior to registration

    • Gastroesophageal junction tumors must be Siewert type I/II
  • Required diagnostic workup for study entry:

    • History/physical examination prior to registration
    • Computed tomography (CT) of the chest/abdomen with intravenous contrast within 28 days prior to registration; If CT contrast is contraindicated magnetic resonance imaging (MRI) of the chest/abdomen without contrast is permitted
    • Bronchoscopy for squamous cell carcinoma (SCC) tumors that are adjacent to the airway to exclude a tracheoesophageal fistula within 42 days prior to registration
    • Endoscopic ultrasound (if technically feasible) within 90 days prior to registration
    • Whole body positron emission tomography (PET)/CT scan within 42 days prior to registration: Note: scan will be used for radiation treatment planning, in addition to ruling out metastatic disease
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 within 14 days prior to registration

  • Adequate hematologic function within 14 days prior to registration defined as follows Absolute neutrophil count ≥ 1,500/mcL (within 14 days prior to registration) Hemoglobin ≥ 9 gm/dL (within 14 days prior to registration) Platelets ≥ 100,000/mcL (within 14 days prior to registration)

  • Adequate renal function within 14 days prior to registration defined as follows Creatinine clearance of ≥ 50 ml/min (as calculated by Cockcroft-Gault equation) (within 14 days prior to registration)

  • Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (within 14 days prior to registration)

  • AST/ALT ≤ 2.5 x ULN

  • Patients for whom non-operative management is a viable option in the opinion of a thoracic surgeon and/or multidisciplinary team and are candidates for chemoradiation; this does not preclude patients from receiving surgery after chemoradiation if felt to me medically indicated;

  • Patients must, in the opinion of a treating gastroenterologist, have a tumor that is amenable to intratumoral injection with at least 1 mL (1 x 10^12 vp/mL) of OBP-301 and be a candidate for 3 endoscopy procedures

  • Female patients of child bearing potential must have a negative serum/urine pregnancy test within 14 days prior to study entry. A female not of childbearing potential is one who has undergone a hysterectomy, bilateral oophorectomy, tubal ligation, or who has had no menses for 12 consecutive months

  • Patients of reproductive potential must agree to use effective contraception for the duration of study treatment as well as 6 months (for women) or 12 months (for men) after the last administered injection of OBP-301. Effective contraception includes oral contraceptives, implantable hormonal contraception, double-barrier method or intrauterine device

  • The patient must provide study-specific informed consent prior to study entry

  • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial

  • Known acute or chronic hepatitis B or C infection (testing not required prior to study entry in patients with no known history of hepatitis B or C)

    • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
    • For patients with a history of hepatitis C virus (HCV) infection, they must (i) have been treated and cured, (ii) for patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
  • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months prior to study entry are eligible for this trial

Exclusion Criteria:

  • Definitive clinical or radiologic evidence of metastatic disease including:

    • Positive malignant cytology of the pleura, pericardium or peritoneum
    • Radiographic evidence of involvement of any adjacent mediastinal structure, e.g. aorta, trachea, which would increase the risk of repeated endoscopic interventions
    • Tracheoesophageal fistula
    • Radiographic evidence of distant organ involvement
    • Non-regional lymph nodes that cannot be contained within a radiation field
  • More than 1 esophageal lesion

  • Prior systemic chemotherapy for the study cancer

  • Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields

  • Biopsy-proven tumor invasion of the tracheobronchial tree or presence of tracheoesophageal fistula or recurrent laryngeal or phrenic nerve paralysis

  • For patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, a New York Heart Association functional classification 2C or worse

  • Uncontrolled diabetes

  • Infection requiring IV antibiotics at the time of registration

  • Patients requiring immunosuppressive medications including chronic suppressive steroid therapy (greater than the equivalent of 20 mg/day of prednisone), methotrexate, azathioprine and TNF-alpha blockers within 7 days prior to study entry

  • Received live vaccine within 30 days prior to registration

  • Received a blood transfusion, hematopoietic agent; granulocyte-colony stimulating factor (G-CSF), and/or oxygen supplementation within 7 days before the screening lab

  • Breast feeding females

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Treatment (OBP-301, carboplatin, paclitaxel, radiation)

Patients receive OBP-301 (1×10^12 vp/mL) by intra-tumoral injection via endoscopy on days -3, 12, and 26. Patients also receive paclitaxel IV (50 mg/m^2) over 60 minutes followed by carboplatin IV (AUC 2) over 30 minutes and on days 1, 8, 15, 22, and 29, and undergo radiation therapy (1.8 Gy/faction) on Monday through Friday beginning day 1 for 28 fractions (50.4 Gy total) over 5.5 weeks. All treatment continues in the absence of disease progression or unacceptable toxicity.

Intravenously (IV)

其他名称:
  • 芽生威
  • 卡宝
  • 卡铂六醇
  • 卡铂
  • 卡布辛
  • 卡波索尔
  • 卡博泰克
  • CBDCA
  • 迪普拉塔
  • 埃卡尔
  • JM-8
  • 内洛林
  • 新铂金
  • 副铂
  • 副铂 AQ
  • 对铂
  • 铂金瓦斯
  • 核糖体

Intravenously (IV)

其他名称:
  • 紫杉醇
  • 安扎塔克斯
  • Asotax
  • 布里他索
  • 普拉塞尔
  • 紫杉醇音乐会

Daily fractions

其他名称:
  • 癌症放疗
  • 照射
  • 辐照
  • 辐射
  • 放射治疗,NOS
  • 放疗
  • 转播
  • 治疗、放射
  • 放射治疗

Intra-tumoral injection

其他名称:
  • OBP-301
  • 端粒酶™

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Number of Participants Experiencing Any Dose-Limiting Toxicities (DLTs)
大体时间:From start of protocol treatment until 30 days after the completion of chemoradiation, approximately 10 weeks.

Adverse events are graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, which grades adverse event severity as follows: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, 5 = death related to adverse event. A DLT is defined as the following that are definitely or probably attributed to OBP-301:

  • Any grade ≥3 adverse event EXCEPT for the following:

    • Grade 3 nausea/vomiting
    • Grade 3 esophagitis or dehydration
    • The first occurrence of grade 3/4 neutropenia
    • Grade 3/4 lymphopenia (since this is a known toxicity of chemoradiation and OBP-301)
  • Any toxicity that leads to a >14-day cumulative delay in chemoradiation.

If 0 or 1 participants of 6 participants experienced a DLT, then the treatment regimen would be considered safe (and 9 more would be accrued for secondary endpoints). Otherwise, the regimen would be deemed too toxic and a second cohort of six participants would be accrued to a lower dose of OBP-301 (1 x 10^11 vp/mL).

From start of protocol treatment until 30 days after the completion of chemoradiation, approximately 10 weeks.

次要结果测量

结果测量
措施说明
大体时间
1年和2年的参与者人数
大体时间:1和2年
1和2年
Number of Participants by Highest Grade Adverse Event Reported
大体时间:From start of protocol treatment to last follow-up. Maximum follow-up was 28.7 months.

The Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 grades adverse event severity as follows: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, 5 = death related to adverse event. Summary data is provided in this outcome measure; see Adverse Events Module for specific adverse event data.

From start of protocol treatment to last follow-up. Maximum follow-up was 28.7 months.
Number of Participants With Clinical Complete Response (cCR)
大体时间:6-8 weeks after completion of chemoradiation, approximately 11.5-13.5 weeks from baseline.

Clinical complete response is defined as grossly free of disease as determined by a visual inspection or if the visual inspection was not certain, then a negative biopsy. The number of participants is determined for two populations:

  • Complete case analysis only includes eligible participants who started protocol treatment and were assessed for cCR;
  • Sensitivity analysis includes all eligible participants who started protocol treatment and counts participants without an assessment as not achieving a cCR.
6-8 weeks after completion of chemoradiation, approximately 11.5-13.5 weeks from baseline.
Number of Participants Alive Without Progression at 1 and 2 Years
大体时间:At 1 and 2 years

Progression is defined as pathologically confirmed recurrence of local disease or clinical evidence of distant disease.

At 1 and 2 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 首席研究员:Geoffrey Y Ku、NRG Oncology

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年12月2日

初级完成 (实际的)

2024年10月6日

研究完成 (估计的)

2029年10月6日

研究注册日期

首次提交

2020年5月12日

首先提交符合 QC 标准的

2020年5月12日

首次发布 (实际的)

2020年5月18日

研究记录更新

最后更新发布 (实际的)

2026年10月1日

上次提交的符合 QC 标准的更新

2026年9月9日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

关键字

其他研究编号

  • NRG-GI007
  • U10CA180868 (美国 NIH 拨款/合同)
  • NRG-GI007 (其他标识符:CTEP)
  • NCI-2020-02320 (注册表标识符:CTRP (Clinical Trial Reporting Program))
  • NRG-GI007 (其他标识符:NRG Oncology)

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅